Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MRDPL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HLL2-PBD
|
|||||
| Synonyms |
HLL2-PBD (ADC Therapeutics)
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics SA
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Epratuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Inter-chain cysteine.
|
|||||
| Combination Type |
Tesirine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.